Scholarlink

<p>Pharmacogenomics (PGx) enables personalized therapy by considering individual genetic variation. However, North African populations remain underrepresented in global PGx databases despite their substantial and unique genetic diversity, which can strongly influence drug response. This study characterizes the pharmacogenomic landscape of 109 Moroccan individuals using whole-genome sequencing data. Across 8289 candidate pharmacogenes, we identified 129,021 novel variants, predominantly within <i>DPYD</i>, <i>CYP2C19</i>, and <i>SLCO1B1</i>, underscoring the region’s considerable genomic diversity. Analysis of 17 clinically relevant pharmacogenes with established CPIC drug guidelines revealed the high prevalence of SLCO1B1*15, UGT1A1*80 + *28, CYP2C19*17, and <i>VKORC1</i> rs9923231 alleles. Additionally, HLA-A and HLA-B genotyping identified frequent alleles (HLA-A*03:01, HLA-A*30:02, HLA-B*51:01) previously associated with adverse drug reactions. Collectively, these findings provide a foundational resource for population-specific pharmacogenomic interpretation and support the advancement of precision medicine in Morocco and across North Africa.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacogenomic landscape of a Moroccan cohort: enhancing global diversity and addressing the North African gap

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Souad Kartti,
  • Mohammed Walid Chemao-Elfihri,
  • Mohammed Hakmi,
  • Marouane Aherkou,
  • Rachid ElJaoudi,
  • Lahcen Balouch,
  • Elmostafa El Fahime,
  • Lahcen Belyamani,
  • Saber Boutayeb

摘要

Pharmacogenomics (PGx) enables personalized therapy by considering individual genetic variation. However, North African populations remain underrepresented in global PGx databases despite their substantial and unique genetic diversity, which can strongly influence drug response. This study characterizes the pharmacogenomic landscape of 109 Moroccan individuals using whole-genome sequencing data. Across 8289 candidate pharmacogenes, we identified 129,021 novel variants, predominantly within DPYD, CYP2C19, and SLCO1B1, underscoring the region’s considerable genomic diversity. Analysis of 17 clinically relevant pharmacogenes with established CPIC drug guidelines revealed the high prevalence of SLCO1B1*15, UGT1A1*80 + *28, CYP2C19*17, and VKORC1 rs9923231 alleles. Additionally, HLA-A and HLA-B genotyping identified frequent alleles (HLA-A*03:01, HLA-A*30:02, HLA-B*51:01) previously associated with adverse drug reactions. Collectively, these findings provide a foundational resource for population-specific pharmacogenomic interpretation and support the advancement of precision medicine in Morocco and across North Africa.